Literature DB >> 17275887

Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.

A V Iakhiaev1, A Nalian, K Koenig, S Idell.   

Abstract

Fibrin deposition is a hallmark of pleural inflammation and loculation but understanding of mechanisms by which mesothelial cells regulate intrapleural fibrinolysins remains incomplete. We speculated that pleural mesothelial cells regulate local fibrinolytic capacity via processing of single chain urokinase type plasminogen activator (scuPA). Pretreatment of human pleural mesothelial (MeT-5A) cells with TGF-beta or thrombin, either alone or in combination, inhibited urokinase (uPA)-mediated fibrinolysis by MeT-5A. Thrombin, unlike TGF-beta, inhibited fibrinolysis without induction of PAI-1, suggesting that thrombin-mediated cleavage of scuPA inhibits the fibrinolytic capacity of MeT-5A cells. Thrombin cleaves both purified scuPA as well as that secreted by MeT-5A cells and cell surface thrombomodulin accelerates thrombin-mediated cleavage of scuPA to inhibit cellular fibrinolytic activity. Molecular dynamics analyses demonstrated that thrombin-cleaved scuPA (uPAt) do not acquire a catalytically active conformation and that secondary plasminogen binding sites of uPA implicated in plasminogen activation are distorted in uPAt, explaining, at least in part, why uPAt is a poor enzyme. uPAt was detectable in transudative and exudative pleural effusions from patients. Intrapleural administration of scuPA generated increased levels of uPAt in PF of rabbits with pleural injury and loculation induced by tetracycline in vivo. This pathway is operative in diverse forms of pleural injury, restricts the urokinase-dependent fibrinolytic capacity of pleural mesothelial cells and contributes to local control of fibrinolytic activity via processing of endogenous or exogenous scuPA within the pleural compartment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275887      PMCID: PMC2100409          DOI: 10.1016/j.thromres.2006.12.001

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  29 in total

1.  The matrix unloaded: aerosolized heparin or urokinase for pulmonary fibrosis.

Authors:  Steven Idell
Journal:  Am J Respir Crit Care Med       Date:  2003-12-01       Impact factor: 21.405

2.  The discovery of TAFI.

Authors:  M Nesheim; L Bajzar
Journal:  J Thromb Haemost       Date:  2005-10       Impact factor: 5.824

3.  Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.

Authors:  B A Katz; R Mackman; C Luong; K Radika; A Martelli; P A Sprengeler; J Wang; H Chan; L Wong
Journal:  Chem Biol       Date:  2000-04

Review 4.  Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.

Authors:  Steven Idell
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

5.  The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin.

Authors:  K C Robbins; L Summaria; B Hsieh; R J Shah
Journal:  J Biol Chem       Date:  1967-05-25       Impact factor: 5.157

6.  Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.

Authors:  V Gurewich; R Pannell; S Louie; P Kelley; R L Suddith; R Greenlee
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

Review 7.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

8.  Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits.

Authors:  Steven Idell; Andrew Mazar; Douglas Cines; Alice Kuo; Graham Parry; Susan Gawlak; Jose Juarez; Kathy Koenig; Ali Azghani; Will Hadden; Jerry McLarty; Edmund Miller
Journal:  Am J Respir Crit Care Med       Date:  2002-10-01       Impact factor: 21.405

9.  Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

Authors:  D C Rijken; D Collen
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

10.  Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.

Authors:  O Matsuo; D C Rijken; D Collen
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

View more
  3 in total

1.  Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells.

Authors:  Roghieh Djafarzadeh; Matthias Sauter; Susan Notohamiprodjo; Elfriede Noessner; Pankaj Goyal; Wolfgang Siess; Markus Wörnle; Andrea Ribeiro; Susanne Himmelein; Thomas Sitter; Peter J Nelson
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

2.  Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.

Authors:  Cheng-Ying Hsieh; Joen-Rong Sheu; Chih-Hao Yang; Wei-Lin Chen; Jie-Heng Tsai; Chi-Li Chung
Journal:  Int J Mol Sci       Date:  2019-10-13       Impact factor: 5.923

3.  Structural and Functional Determinants of Rodent and Human Surfactant Protein A: A Synthesis of Binding and Computational Data.

Authors:  Armen Nalian; Todd M Umstead; Ching-Hui Yang; Patricia Silveyra; Neal J Thomas; Joanna Floros; Francis X McCormack; Zissis C Chroneos
Journal:  Front Immunol       Date:  2019-11-07       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.